SynBiotic SE (FRA:SBX)

Market Cap	19.95M
Revenue (ttm)	3.86M
Net Income (ttm)	-10.63M
Shares Out	n/a
EPS (ttm)	-2.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	600
Average Volume	317
Open	2.810
Previous Close	2.860
Day's Range	2.795 - 2.890
52-Week Range	2.705 - 6.720
Beta	n/a
RSI	51.40
Earnings Date	Nov 14, 2025

About SynBiotic SE

SynBiotic SE engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety. It also offers hemp, cannabinoids, dietary supplements, and cosmetic products; medical cannabis products; and cannabis products for recreational use under the Hempamed, Princess Stardust, The Hempany, and Hempamed Rx brand names. The company was formerly known as Ledgertech SE and changed its name to SynBiotic SE. SynBiotic SE was founded in 2017 and is based in Munich, Germany.

• Industry: Pharmaceutical Preparations
• Founded: 2017
• Employees: 55
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: SBX

Financial Performance

In 2023, SynBiotic SE's revenue was 3.86 million, a decrease of -52.71% compared to the previous year's 8.17 million. Losses were -10.63 million, -56.36% less than in 2022.